# A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

Source: https://onco.cc/trials/nct06843447/  
OnCo record `nct06843447` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Raludotatug deruxtecan, Carboplatin, Paclitaxel / nab-paclitaxel in ovarian cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) is a phase 1/2 interventional study registered as NCT06843447 by Merck Sharp & Dohme LLC, with 605 participants planned, started 2025-04-15 and due to reach its primary completion in 2029-03-27. Interventions recorded: Raludotatug Deruxtecan, Carboplatin, Paclitaxel, Bevacizumab, Rescue Medication. Conditions listed: Ovarian Cancer Recurrent. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06843447
- Phase: 1/2
- Setting: A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With Advanced High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (REJOICE-Ovarian02)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 605

## Sources

- ClinicalTrials.gov NCT06843447: https://clinicaltrials.gov/study/NCT06843447

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Raludotatug deruxtecan](https://onco.cc/drugs/raludotatug-deruxtecan/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06843447.json